Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
复制标题
痘苗病毒重组表达单纯疱疹病毒 1 型糖蛋白 D 可预防小鼠体内的潜伏性疱疹。
DOI：
10.1126/science.2986288
复制
发表时间：
1985
期刊：
影响因子：
56.9
通讯作者：
B. Moss
中科院分区：
文献类型：
--
作者：
K. Cremer;M. Mackett;C. Wohlenberg;A. Notkins;B. Moss
在人类中，单纯疱疹病毒会引起原发感染，然后通常是潜伏的神经节细胞感染，并持续终生。由于这些潜伏感染可能会周期性地复发，因此需要能够预防原发和潜伏的单纯疱疹病毒感染的疫苗。构建了含单纯疱疹病毒1型(HSV-1)糖蛋白D基因的感染性痘苗病毒重组体。感染了这些重组病毒的组织培养细胞合成了一种糖基化蛋白，其质量与HSV-1产生的糖蛋白D相同(60000道尔顿)。用这些重组病毒中的一种通过皮内、皮下或腹膜途径免疫小鼠，可产生中和HSV-1的抗体，并保护小鼠免受随后的HSV-1或HSV-2的致命攻击。重组病毒的免疫也保护了大多数小鼠免受三叉神经节潜伏的HSV-1感染。这是第一次证明基因工程疫苗可以防止潜伏期的发展。
In humans, herpes simplex virus causes a primary infection and then often a latent ganglionic infection that persists for life. Because these latent infections can recur periodically, vaccines are needed that can protect against both primary and latent herpes simplex infections. Infectious vaccinia virus recombinants that contain the herpes simplex virus type 1 (HSV-1) glycoprotein D gene under control of defined early or late vaccinia virus promoters were constructed. Tissue culture cells infected with these recombinant viruses synthesized a glycosylated protein that had the same mass (60,000 daltons) as the glycoprotein D produced by HSV-1. Immunization of mice with one of these recombinant viruses by intradermal, subcutaneous, or intraperitoneal routes resulted in the production of antibodies that neutralized HSV-1 and protected the mice against subsequent lethal challenge with HSV-1 or HSV-2. Immunization with the recombinant virus also protected the majority of the mice against the development of a latent HSV-1 infection of the trigeminal ganglia. This is the first demonstration that a genetically engineered vaccine can prevent the development of latency.